Celyad SA (CYAD) Announces Completion of NKR-2 Phase I in AML
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Celyad Completes the NKR-2 Phase I Trial with Successful Safety Follow-up of the Fourth Dose Level
September 9, 2016 1:01 AM EDTNo safety issues or dose limiting toxicity reported. The trial was a single administration, dose escalation study evaluating the safety and feasibility of NKR-2 T-cell therapy in patients with Acute Myeloid Leukemia or Multiple Myeloma. Results of the trial are expected to be available in late Q4 2016
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--
Regulatory News:
Celyad (Paris: CYAD) (Brussels: CYAD) (Euronext Brussels and Paris, and NASDAQ:... More
